🟢 Summit Therapeutics is trading 5.7% up in pre-market after partner Akeso reported significant ivonescimab overall-survival results

Summit Therapeutics is trading at $18.55 (+5.70%) after partner Akeso reported statistically significant, clinically meaningful overall-survival results for ivonescimab versus pembrolizumab in PD-L1-positive advanced lung cancer.

• Updated HARMONi-2 data are scheduled for presentation at WCLC 2026 on September 15, 2026, providing an imminent clinical catalyst.
• The move is company-specific rather than driven by today’s weaker futures.